# EDGAR Filing Document

**Accession Number:** 0001527728
**File Stem:** 0001214659-25-017353
**Filing Date:** 2025-11
**Character Count:** 9282
**Document Hash:** 79c7ceda0923e32d59b4ef149b6c2541
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-017353.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001214659-25-017353

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lunai Bioworks Inc.
- **CENTRAL INDEX KEY:** 0001527728
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452259340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-86428
- **FILM NUMBER:** 251536752

**BUSINESS ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067
- **BUSINESS PHONE:** 45 39179840

**MAIL ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO INC.
- **DATE OF NAME CHANGE:** 20240213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO BIOSCIENCES INC.
- **DATE OF NAME CHANGE:** 20230807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Enochian Biosciences Inc.
- **DATE OF NAME CHANGE:** 20230804
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** William Anderson Wittekind
- **CENTRAL INDEX KEY:** 0001753085

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 8581 SANTA MONICA BLVD
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90069

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 23)**

**Lunai Bioworks Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**29350E203**

*(CUSIP Number)*

**William Anderson Wittekind**<br>8581 Santa Monica Blvd.

#317<br>West Hollywood CA 90069<br>(424) 235-1810

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/25/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **29350E203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**William Anderson Wittekind** | Name of reporting person<br>**William Anderson Wittekind** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**560665.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1252656.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**560665.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1252656.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1813321.00** | Aggregate amount beneficially owned by each reporting person<br>**1813321.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.8%** | Percent of class represented by amount in Row (11)<br>**6.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The number of shares disclosed in Rows 7 and 9 consist of (i) 326,576 shares owned by William Anderson Wittekind ("Wittekind"); (ii) 84,032 shares owned by Weird Science LLC ("Weird Science"); (iii) 63,393 shares owned by the William Anderson Wittekind 2020 Annuity Trust, a grantor retained annuity trust  of which Wittekind is the sole trustee (the "Wittekind 2020 Annuity Trust"); (iv) 45,057 shares owned by the Dybul 2020 Angel Annuity Trust, a grantor retained trust of which Wittekind is the sole trustee (the "Dybul 2020 Annuity Trust"); (v) 5,000 shares owned by the Ty Mabry 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is sole trustee (the "Mabry 2021 Annuity Trust"); and (vi) 36,608 shares owned by the William Anderson Wittekind 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2021 Annuity Trust" and, together with the Wittekind 2020 Annuity Trust, the Dybul 2020 Annuity Trust and the Mabry 2021 Annuity Trust, the "Trusts"). In his capacity as the sole manager of Weird Science, Wittekind has sole voting and sole dispositive power over the shares owned by Weird Science. In his capacity as the sole trustee of the Trusts, Wittekind has sole voting power and sole dispositive power over the shares owned by the Trusts.
(2) The number of shares disclosed in Rows 8 and 12 consists of (i) 8,813 shares owned by Wittekind and Serhat Gumrukcu, Wittekind's spouse ("Gumrukcu"), as joint tenants with a right of survivorship ("JTWROS") and (ii) 1,243,844 shares owned by Gumrukcu, of which Wittekind shares voting and dispositive power through a power of attorney dated June 24, 2022. Pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023, the 12,438,431 shares owned by Gumrukcu are subject to a writ of attachment to secure the plaintiffs' claim in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123).
(3) The percentage ownership disclosed in Row 13 is based upon the sum of (i) 23,432,391 shares outstanding as of November 10, 2025, as disclosed in the Issuer's Form 10-Q filed with the Commission on November 14, 2025 plus (ii) 3,133,333 shares sold by the Issuer according to the Form 8-K filed with the Commission on November 25, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Lunai Bioworks Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2080 Century Park East, Suite 906, Los Angeles, CA, 90067

This Amendment No. 23 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company ("Weird Science") and William Anderson Wittekind, a member and manager of Weird Science ("Wittekind") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Lunai Bioworks Inc. (the "Issuer") received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the "Merger Agreement") by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer ("Merger Sub"), Renovaro Biopharma, Inc., a Delaware corporation then known as Enochian Biopharma Inc. ("Target"), and Weird Science, in its capacity as the majority stockholder of the Target, as amended by Amendment Nos. 1 through 22 thereto. Wittekind is the sole reporting person under this Amendment No. 23 to Schedule 13D (the "Reporting Person").

Capitalized terms used but not defined in this Amendment No. 23 have the meanings given to such terms in the initial Schedule 13D, as amended by Amendment Nos. 1 through 22 thereto.

On November 25, 2025 the Issuer filed a Form 8-K reporting that it had sold 3,133,333 shares of Common Stock. This Amendment No. 23 is being filed to report the change in the Reporting Person's beneficial ownership from 7.8% to 6.8%.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 23, including the accompany notes, is hereby incorporated by reference into this Item 5(a).

**(b)**
The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 23, including the accompany notes, is hereby incorporated by reference into this Item 5(b).

**(c)**
Not Applicable

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Not Applicable.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** William Anderson Wittekind

**Signature:** /s/ William Anderson Wittekind

**Name/Title:** William Anderson Wittekind

**Date:** 11/28/2025